Tweet Park B, Nicaise AM, Tsitsipatis D, Pirvan L, Zucha D, Munteanu A, Prasad P, De Novales MLL, Bulgaru C, Kollyfas R, Whitten J, Willis CM, Culig L, Llewellyn J, Ionescu RB, Mekdad M, Simões-Abade MBC, Krzak G, Fan J, De S, Ellis MO, Cubero MS, Spathopoulou A, Peruzzotti-Jametti L, Leonardi T, Balmus G, Edenhofer…
Month: October 2025
Recovery takes time
Tweet I have got off on one about Progression independent of relapse as a measure of worsening. Here they look at time for worsening and it says you can recover over a long time. Mostert J, Strijbis EM, D’Haeseleer M, Moral E, Brieva L, Comtois J, Repovic P, Bowen JD, Cutter G, Koch M. Extended…
🐱Another Kitty Update😽
The weekend has arrived, and I hope you can do something that brings joy to your life! For the past few weeks, I have been nursing a kitten back to health. When she was basically dropped at our front door by her mother, she had a nasty infection in both of her eyes. At first,…
Future treatment may get easier
Tweet I am often accused of being a glass half empty Yorkshireman and never sufficiently positive. But I think MS can learn from Lupus and it’s little cousin called neuromyelitis optica or historically Devics multiple sclerosis. CAR-T therapy where you make T cells target something else using a chimeric antigen receptor. Chimeric because the antigen…
Octave wins grant to develop blood test for measuring MS progression
A new grant from the Valhalla Foundation will help Octave Bioscience advance the development of a biomarker blood test for detecting disease progression in people with multiple sclerosis (MS). The […] The post Octave wins grant to develop blood test for measuring MS progression appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Embrace the Weird
“We’re all a little weird. And life is a little weird. And when we find someone whose weirdness is compatible with ours, we join up with them and fall into mutually satisfying weirdness—and call it love—true love.” ― Robert Fulghum … Continue reading → Source: blog.mymsaa.org
With new data, Quantum moves closer to launching trial of Lucid-MS
Quantum Biopharma says it is closer to initiating a Phase 2 clinical trial — one involving people living with multiple sclerosis (MS) — to test its experimental therapy Lucid-MS after […] The post With new data, Quantum moves closer to launching trial of Lucid-MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
When living with MS, we have to be open to change in our routine
“We’ve always done it this way” was the phrase I most despised in the Army whenever I questioned a tactic or technique. I’m not saying routine and doctrine aren’t important […] The post When living with MS, we have to be open to change in our routine appeared first on Multiple Sclerosis News Today. Source:…
Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS
Zenas Biopharma has acquired global rights to develop the BTK inhibitor orelabrutinib to treat multiple sclerosis (MS) and other diseases. The deal with orelabrutinib’s developer, Innocare Pharma, includes rights to […] The post Zenas acquires BTK inhibitor in Phase 3 trials for progressive MS appeared first on Multiple Sclerosis News Today. Source: multiplesclerosisnewstoday.com
Dropping antibody levels
Tweet Two treatments that block vaccine responses are fingolimod and anti CD20 antibodies. They also block circulating antibodies and this can be a biomarker for infection. Here they say antibody IgG don’t drop after a switch from fingo to ocrelizumab or rituximab. However they look upt a year and IgG drops after antiCD20 are slow…